Stevanato Group S.p.a. · NYSE:STVN
Stevanato — Q1 2026 Earnings Presentation
10 slides from Stevanato's earnings presentation, May 7, 2026
Slide 1: First Quarter 2026 Financial Results
Stevanato Group Investor Relations First Quarter 2026 Financial Results May 7, 2026 Lisa Miles, Chief Communication and IR Officer Good morning, and thank you for joining us. Today, we have a change to how we normally manage our earnings calls. Franco Stevanato, our Chief Executive Officer, is recov
Slide 2: First Quarter Performance
Stevanato Group Investor Relations First Quarter 2026 Financial Results May 7, 2026 Lisa Miles, Chief Communication and IR Officer, on behalf of Franco Stevanato, Chief Executive Officer So, let’s get started. Today, we’ll review our first-quarter performance, share an update on our investment proje
Slide 3: Biopharmaceutical and Diagnostics Solutions Segment
Stevanato Group Investor Relations First Quarter 2026 Financial Results May 7, 2026 spread across a handful of large players. Today, market demand is extending into many other traditional large pharma and emerging biotech players driven by biologics. The demand is wide-ranging from traditional 1.5 M
Slide 4: Two Main Priorities
Stevanato Group Investor Relations First Quarter 2026 Financial Results May 7, 2026 The team is squarely focused on two main priorities. • First, we continue executing the optimization plan, and much work has been done to improve operational efficiency over the last 18 months. As we right-sized oper
Slide 5: Latina Ramp-Up
Stevanato Group Investor Relations First Quarter 2026 Financial Results May 7, 2026 Turning to Latina, the current ramp-up remains centered on bringing high-value syringe capacity into service and advancing customer validations. At the same time, we are preparing for the next phase of expansion for
Slide 6: First Quarter 2026 Financial Results
Stevanato Group Investor Relations First Quarter 2026 Financial Results May 7, 2026 Marco Dal Lago, Chief Financial Officer Thanks, Lisa. Before I begin, I’d like to clarify that all comparisons refer to the first quarter of 2025, unless otherwise specified. Let’s start on page 10. In the first quar
Slide 7: Segment Financial Results
Stevanato Group Investor Relations First Quarter 2026 Financial Results May 7, 2026 Adjusted EBITDA increased 14% to €65.5 million and adjusted EBITDA margin increased 150 basis points to 23.9% in the first quarter of 2026. Segment Financial Results Moving to Segment results on page 11. Biopharmaceu
Slide 8: Engineering Segment
Stevanato Group Investor Relations First Quarter 2026 Financial Results May 7, 2026 • And last, the impact of tariffs, some of which are expected to be recovered in future periods. As a result, gross profit margin decreased by 300 basis points to 28.3%. For the first quarter of 2026, operating profi
Slide 9: Guidance
Stevanato Group Investor Relations First Quarter 2026 Financial Results May 7, 2026 For the first quarter of 2026, capital expenditures totaled €67.6 million, with more than 90% related to growth investments for high-value solutions in Fishers and Latina. In the first quarter of 2026, net cash from
Slide 10: Looking Ahead
Stevanato Group Investor Relations First Quarter 2026 Financial Results May 7, 2026 Our capital investments are aligned with market demand, and we are maximizing our operational flexibility through ongoing initiatives to optimize our global footprint to meet customer needs. We will continue to lever